Polymerase basic protein 2 (PB2) (influenza virus) inhibitor Treatment of influenza A infection

Research output: Contribution to journalArticlepeer-review


Pimodivir (VX-787, JNJ-63623872) is an investigational anti-influenza drug, currently undergoing clinical development. Pimodivir is a non-nucleoside analogue that targets the cap-binding activity of the influenza A virus PB2 polymerase subunit. It is potent against influenza A, including against adamantanes and neuraminidase inhibitor-resistant strains. In a phase IIb study of naturally acquired influenza A virus infection, a statistically significant and dose-dependent decrease in virus load was observed. Diarrhea was the most common adverse event reported and was typically mild. Pimodivir is a substrate for CYP3A4 metabolism but itself has no inhibitory or induction effects on the isoenzyme. It is also a substrate for P-glycoprotein and OATP1B1 and also inhibits P-glycoprotein. Specific drug interactions have not yet been studied. Pimodivir 600 mg twice daily for 5 days has been selected and is undergoing further evaluation in phase III clinical trials.

Original languageEnglish (US)
Pages (from-to)339-348
Number of pages10
JournalDrugs of the Future
Issue number5
StatePublished - Jan 1 2019


  • Influenza A
  • JNJ-63623872
  • Pimodivir
  • Polymerase basic protein 2 (PB2)
  • VX-787

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Polymerase basic protein 2 (PB2) (influenza virus) inhibitor Treatment of influenza A infection'. Together they form a unique fingerprint.

Cite this